| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/25/2003 | US6525047 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair |
| 02/25/2003 | US6525033 2', 3' dideoxynucleoside compounds; 2',3'-dideoxycytidine (beta -L-FddC), beta -L-2',3'-dideoxy-5-fluorocytidine (beta-L-ddC); beta-D-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-dioxolane |
| 02/25/2003 | US6525029 Contacting cell with (i) a recombinant adenoviral vector comprising a transgene and (ii) a recombinant adenoviral vector encoding a TNF receptor fusion protein comprising the extracellular domain |
| 02/25/2003 | US6525026 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 02/25/2003 | US6525025 Controlling apoptosis; cardiovascular disorders; central nervous system disorders |
| 02/25/2003 | US6525023 Vascular smooth muscle cell growth factor |
| 02/25/2003 | US6525022 Receptor specific atrial natriuretic peptides |
| 02/25/2003 | US6525021 Cardioprotection, hypoxia, anoxia or ischemia |
| 02/25/2003 | US6525020 For drug delivery |
| 02/25/2003 | US6525019 Use of melanin for inhibition of angiogenesis and macular degeneration |
| 02/25/2003 | US6525018 Intestinal trefoil factor (ITF), spasmolytic peptide (SP), pS2; treatment of a disruption of the corneal epithelium |
| 02/25/2003 | US6525017 Using glutathiane to protect neurons from injury |
| 02/25/2003 | US6524854 Antisense inhibition of PKA regulatory subunit RII alpha expression |
| 02/25/2003 | US6524840 Polynucleotides, host cell expression systems, the encoded proteins, polypeptides and peptides |
| 02/25/2003 | US6524836 Zace1: a human metalloenzyme |
| 02/25/2003 | US6524835 Synthetic α-L-iduronidase and genetic sequences encoding same |
| 02/25/2003 | US6524834 Protein capable of hydrolyzing organophosphorous acetylcholinesterase inhibitors for use as poison antedote |
| 02/25/2003 | US6524826 Polynucleotides encoding cortistatin polypeptides |
| 02/25/2003 | US6524821 Anti-apoptotic compositions comprising the R1 subunit of herpes simplex virus ribonucleotide reductase or its N-terminal portion; and uses thereof |
| 02/25/2003 | US6524819 And their use in the screening for compounds of use in characterization, diagnosis, and treatment of conditions such as Alzheimer's disease, Down syndrome and other forms of dementia |
| 02/25/2003 | US6524815 A promoter which is active in the vascular endothelium and to its use for expressing genes of interest in this tissue |
| 02/25/2003 | US6524813 Novel polynucleotides and polypeptides of the spo0J family derived from Staphylococcus |
| 02/25/2003 | US6524806 Methods of screening for ligands of human hemetopoietin receptor HU-B1.219 |
| 02/25/2003 | US6524802 Methods of detecting growth differentiation factor-14 |
| 02/25/2003 | US6524799 DNA encoding sparc-related proteins |
| 02/25/2003 | US6524623 Therapeutic compositions and methods of use thereof |
| 02/25/2003 | US6524622 Method of controlling the working time of a gypsum composition in the bone treatment |
| 02/25/2003 | US6524591 Monocyte locomotion inhibitory factor |
| 02/25/2003 | US6524585 Using the indolicidin analogs to reduce or inhibit microbial growth or survival by contacting an environment with the indolicidin analog |
| 02/25/2003 | US6524582 Methods and compositions for impairing multiplication of HIV-1 |
| 02/25/2003 | US6524580 Method for treating thyroid disorders |
| 02/25/2003 | US6524579 Diagnosing, treating or preventing disorders associated with expression of RNABP, cancer, immune disorder, developmental disorders |
| 02/25/2003 | US6524578 Use of nuclease to reduce wrinkles and discolorations in humans |
| 02/25/2003 | US6524573 Epidermal growth factor receptor activity is induced |
| 02/25/2003 | US6524571 Methioninase gene therapy for tumor treatment |
| 02/25/2003 | US6524570 Polyethylene glycol modified interferon therapy |
| 02/25/2003 | US6524568 Enriched platelet wound healant |
| 02/25/2003 | US6524557 Aerosol formulations of peptides and proteins |
| 02/25/2003 | US6524556 Tricyclic compound dispersed in liquefied hydrofluoroalkane propellant; medium-chain fatty acid triglyceride as dispersant |
| 02/25/2003 | CA2231192C Pharmaceutical combination preparations containing erythropoietin and iron preparations |
| 02/25/2003 | CA2095932C Luteinizing hormone releasing hormone analogs |
| 02/25/2003 | CA2048910C Antimicrobial peptides active against plant pathogens, their method of use and various screening methods pertaining thereto |
| 02/25/2003 | CA2039718C Chimeric dna-rna catalytic sequences |
| 02/25/2003 | CA2032059C Wound treatment employing biologically active peptides |
| 02/24/2003 | CA2394973A1 Mutants of bone morphogenetic proteins |
| 02/22/2003 | CA2355573A1 Method for the synthesis of peptide salts, their use and the pharmaceutical preparations, containing peptide salts |
| 02/20/2003 | WO2003014703A2 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 02/20/2003 | WO2003014702A2 Uses of mammalian cytokine; related reagents |
| 02/20/2003 | WO2003014359A2 A fusion protein |
| 02/20/2003 | WO2003014342A2 Identification of a dna variant associated with adult type hypolactasia |
| 02/20/2003 | WO2003014338A1 Process for producing inactivated virus envelope |
| 02/20/2003 | WO2003014335A1 Process for the maturation of dentritic cells and a vaccine |
| 02/20/2003 | WO2003014329A2 Modulation of angiogenesis by a-beta peptides |
| 02/20/2003 | WO2003014326A2 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/20/2003 | WO2003014322A2 Proteins associated with cell growth, differentiation, and death |
| 02/20/2003 | WO2003014318A2 Methods for treating diabetes and other blood sugar disorders |
| 02/20/2003 | WO2003014310A2 Dna encoding rat bombesin receptor subtype-3 (brs-3) and uses thereof |
| 02/20/2003 | WO2003014309A2 Interleukin-1 receptors in the treatment of diseases |
| 02/20/2003 | WO2003014307A2 Antisense modulation of apolipoprotein(a) expression |
| 02/20/2003 | WO2003014306A2 Antisense modulation of cholesteryl ester transfer protein expression |
| 02/20/2003 | WO2003014304A2 Protonic formulation |
| 02/20/2003 | WO2003014303A2 Molecular interactions in cells |
| 02/20/2003 | WO2003014301A2 Hprp4s as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | WO2003014300A2 TRPS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 02/20/2003 | WO2003014299A2 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 02/20/2003 | WO2003014294A2 Tacis and br3 polypeptides and uses thereof |
| 02/20/2003 | WO2003014293A2 Novel polypeptide analogs and fusions and their methods of use |
| 02/20/2003 | WO2003014160A2 Cd44 variants carrying heparan sulfate chains and uses thereof |
| 02/20/2003 | WO2003014158A1 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use |
| 02/20/2003 | WO2003014157A2 Peptides conjugates, their derivatives with metal complexes and use thereof for magnetic resonance imaging (mri) |
| 02/20/2003 | WO2003014156A2 NEUREGULIN-β ISOFORMS ASSOCIATED WITH NEURONAL PROCESSES |
| 02/20/2003 | WO2003014155A2 Labelled conjugates of p17 protein and their use in aids diagnosis |
| 02/20/2003 | WO2003014153A2 Cellular virus receptors and methods of use. |
| 02/20/2003 | WO2003014152A2 Phosphatidylinositol 5-phosphate-binding proteins |
| 02/20/2003 | WO2003014151A2 Human secreted proteins, their encoding polynucleotides, and uses thereof |
| 02/20/2003 | WO2003014148A2 Human fatty acid-coa ligase |
| 02/20/2003 | WO2003014147A1 Novel depsipeptides and process for preparing same |
| 02/20/2003 | WO2003014146A1 A novel peptide p1 inhibiting differentiation of osteoclasts |
| 02/20/2003 | WO2003014145A2 Peptides that bind to atherosclerotic lesions |
| 02/20/2003 | WO2003014144A2 Molecule |
| 02/20/2003 | WO2003014140A1 Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer |
| 02/20/2003 | WO2003014078A2 Muc7d1 peptides as antifungal and antibacterial agents |
| 02/20/2003 | WO2003014077A2 Crystal forms and mutants of rank ligand |
| 02/20/2003 | WO2003014069A1 Fluoro linkers and their use as linkers for enzyme-activated drug conjugates |
| 02/20/2003 | WO2003013606A1 Thrombomodulin-containing medicinal compositions |
| 02/20/2003 | WO2003013604A2 Migenix agonists and antagonists for use in the treatment of metabolic disorders |
| 02/20/2003 | WO2003013595A1 Compounds and methods for the modulation of immune responses |
| 02/20/2003 | WO2003013594A2 Modulation of antibody formation in mammals, applicability in gene therapy and animal model generation |
| 02/20/2003 | WO2003013592A1 Use of timp-1 as an immunosuppressive |
| 02/20/2003 | WO2003013591A2 Pharmaceutical composition containing caspase-8 and/or caspase-9 useful for overcoming glucocorticoid- and cancer therapy-induced apoptosis resistance of tumours |
| 02/20/2003 | WO2003013590A1 Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer |
| 02/20/2003 | WO2003013589A1 Isulin-containing oral spray and the preparation method thereof |
| 02/20/2003 | WO2003013587A1 Compositions for vascular occlusion |
| 02/20/2003 | WO2003013585A1 Mifaxin agonists and antagonists for use in the treatment of metabolic |
| 02/20/2003 | WO2003013584A1 Xafinix agonists and antagonists for use in the treatment of metabolic disorders |
| 02/20/2003 | WO2003013583A1 Faxigen agonists and antagonists in the treatment of metabolic disorders |
| 02/20/2003 | WO2003013582A1 Genoxit agonists and antagonists for use in the treatment of metabolic disorders |
| 02/20/2003 | WO2003013581A1 Agonists and antagonists of genceptin for the treatment of metabolic disorders |
| 02/20/2003 | WO2003013580A1 Tr xidatin agonists and antagonists treatment of metabolic disorders |
| 02/20/2003 | WO2003013579A1 Lypergix agonists and antagonists for use in the treatment of metabolic disorders |